Cardiology Xagena
A study has determined all-cause mortality in patients with a first myocardial infarct who were treated with Simvastatin ( Zocor ) compared with high-potency statin and Simvastatin / Ezetimibe ( Vytorin ) combination.
Despite statin use, residual cardiovascular risk remains. Therapeutic options include more potent statins or addition of Ezetimibe.
There is no clinical outcome data on the use of Ezetimibe in such patients.
Researchers did retrospective longitudinal study using the United Kingdom General Practice Research Database.
Patients who had survived 30 days after their first acute myocardial infarct ( AMI ), had not received prior statin or
Ezetimibe therapy and were started on a statin within 30 days of AMI were included.
Three groups were identified according to their follow-up: (i) Simvastatin monotherapy; (ii) high-potency statin group ( patients
who started on Simvastatin and switched to Atorvastatin [ Lipitor ] or Rosuvastatin [ Crestor ] ); and (iii) Ezetimibe / statin combination group ( patients who received Ezetimibe in addition to statin ).
A total of 9597 patients ( 57% male, mean age of 65 years ) matched study criteria: Simvastatin ( n=6990; 72.8% ); high-potency statin ( n=1883; 19.6% ); and Ezetimibe / statin combination ( n=724; 7.5% ).
During a mean follow-up of 3.2 years, there were 1134 ( 12% ) deaths.
In the multivariate proportional hazards model, the adjusted hazard ratio ( HR ) for high-potency statin and Ezetimibe
group were 0.72 ( p less than 0.001 ) and 0.96 ( p=0.85 ), respectively.
A similar result was also obtained in the propensity score analysis that took into account covariates that predicted drug treatment groups.
In conclusion, patients switched to a high-potency statin had a significantly reduced mortality compared with Simvastatin monotherapy.
There was no observed mortality benefit in the Ezetimibe group. ( Xagena )
Pauriah M et al, Heart 2014;100:867–872
XagenaMedicine_2014
